| Bioactivity | LTA4H-IN-4 (compound 3) is an orally active LTA4H inhibitor. The IC50 value of LTA4H-IN-4 for hERG is 156 μM. LTA4H-IN-4 can be used in inflammation related studies[1]. |
| Invitro | LTA4H-IN-4 (compound 3) (0-10 μM, 4 h) 完全抑制钙离子载体刺激后的原代外周血单核细胞 (PBMCs) 中 LTB4 释放[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> LTA4H-IN-4 相关抗体: |
| In Vivo | LTA4H-IN-4 (compound 3) (每天 2 次 0-300 mg/kg，间隔 10 小时，持续 7 天， i.v. or p.o.) 在小鼠关节炎模型、大鼠、狗中表现出明显的口服活性，且动物体重没有明显变化，毒理学研究中没有发现明显的不良结果[1]。大鼠、小鼠和狗体内的药代动力学分析[1]Animal model |
| Formula | C19H21N5O2 |
| Molar Mass | 351.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Thoma G, et al. Structure-Guided Elaboration of a Fragment-Like Hit into an Orally Efficacious Leukotriene A4 Hydrolase Inhibitor. J Med Chem. 2024 Mar 28;67(6):5093-5108. |